ARC
LAB icon

Absolute Return Capital’s Standard BioTools LAB Stock Holding History

Absolute Return Capital’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-16,394
Closed -$722K – 1300
2014
Q1 		$722K Buy
+16,394
New +$721K 0.01% 733

Other funds holding LAB

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
NCGI
Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Absolute Return Capital's LAB Position: Q2 2014 in Review

Absolute Return Capital sold out of Standard BioTools (LAB) in Q2 2014, closing a stake of 16,394 shares — an estimated $722K sold.

Absolute Return Capital first reported a position in LAB in Q1 2014 and held it in 1 quarter. The position peaked at $722K in Q1 2014. 104 funds tracked by Wall St. Rank hold LAB as of Q2 2014.

  • Absolute Return Capital reported no remaining Standard BioTools position as of Q2 2014 after selling out during the quarter.
  • Absolute Return Capital sold 16,394 Standard BioTools shares in Q2 2014, an estimated $722K.
  • Absolute Return Capital first reported a position in Standard BioTools in Q1 2014 and held it in 1 quarter.
  • Absolute Return Capital's Standard BioTools position peaked at $722K in Q1 2014.
  • 104 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2014.

Based on Absolute Return Capital's 13F filing for Q2 2014, filed 14 Aug 2014.